Opdualag is a first-in-class, fixed-dose dual immunotherapy combination treatment of the PD-1 inhibitor nivolumab and novel LAG-3-blocking antibody relatlimab
CEPI will expand its partnership with icddr,b in Bangladesh, providing near to the additional US $ 1 million in funding to advance understanding of the Nipah virus
Selvax's goal is to develop safe, effective and immunological-based treatments for a range of hard-to-treat solid tumours
The studies demonstrate a standardized strategy to extend mechanistic modeling and systems pharmacology into drug safety and mode of action assessments that has relevance for drug development and a variety of other contexts
ChipCytometry delivers single-cell targeted spatial proteomics for complex whole-tissue analysis of the tumour microenvironment, as well as deep immune profiling for applications in immunology, neuroscience, and infectious disease
This ninth update of WHO’s guideline on therapeutics includes a recommendation that casirivimab-imdevimab not be used for patients infected with the Omicron variant
Ovarian cancer is one of the most difficult cancers to treat. It is typically not detected until later stages, and about 70 percent of patients will have recurrence after an initial treatment, which is often fatal
This innovative biomanufacturing technology will help to deliver cost-effective viral production that is unmatched in the industry
The products are based on a combination of mushrooms and cannabinoids that have achieved a strong therapeutic effect using low concentrations of THC. The treatment is expected to be launched in Israel, US and UK in H2 2022
The method shows the removal of seven types of PFAS – even when all of them are found in the same unit of fluid – at a level of efficiency that approaches 90%, and it does so within a few minutes
Subscribe To Our Newsletter & Stay Updated
